Navidea, FDA settle on details for NAV5001 trials

08/22/2013 | AuntMinnie.com (free registration)

Navidea Biopharmaceuticals has reached an agreement with the FDA regarding special-protocol assessments for Phase III trials for Navidea's investigational imaging agent NAV5001. The agent targets the brain's dopamine transporters for distinguishing Parkinsonian syndromes with SPECT imaging. Navidea plans to begin the trials this year.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD